Alliance Global Partners analyst James Molloy lowered the firm’s price target on Soligenix (SNGX) to $6 from $10 and keeps a Buy rating on the shares after the company reported recent corporate updates and clinical progress of HyBryte. The firm says its price target represents a sum-of-the-parts.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNGX: